Navigation Links
Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
Date:1/9/2014

DUBLIN, January 9, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/pkv9nd/liver_diseases) has announced the addition of the "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with C-level executives of major companies operating in liver diseases therapeutics market through the means of primary research to finally come up with our results. This research is specially designed to estimate and analyze the performance of liver diseases therapeutics in a global scenario. This research provides in-depth analysis of liver diseases therapeutics market sales, trend analysis by segments.

Key Topics Covered:

1 Preface
1.1 Report Description
1.2 Research Methodology

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Size
3.3 Comparative Analysis Of Global Liver Diseases Therapeutics Market, By Drug Class, 2011 & 2018
3.4 Liver Diseases Therapeutics Market Dynamics
3.5 Porter's Five Forces Analysis For Liver Diseases Therapeutics Market

4 Liver Diseases Classification And Therapy Options
4.1 Alcohol Induced Liver Disease
4.2 Autoimmune Liver Disorder
4.3 Hepatocellular Carcinoma
4.4 Non-Alcoholic Fatty Liver Disease
4.5 Viral/Hepatitis Liver Disorder

5 Liver Diseases Therapeutics Market, By Drug Class
5.1 Immunosuppressants
5.2 Chemotherapy Drugs
5.3 Targeted Therapy Drugs
5.4 Vaccines
5.5 Anti-Viral Drugs
5.6 Immunoglobulins
5.7 Corticosteriods

6 Competitive Landscape

7 Recommendations
7.1 Market Strategy For Success
7.2 Barriers To Be Considered

8 Company Profiles



Companies Mentioned:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Glaxosmithkline Plc
  • F. Hoffmann-La Roche Ltdmerck & Co. Inc
  • Novartis Ag
  • Sanofi S.A
  • Pfizer Inc.
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals
  • Watson Pharmaceuticals, Inc.


For more information visit http://www.researchandmarkets.com/research/pkv9nd/liver_diseases

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
6. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
7. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
8. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
9. Direct Relief Delivers Hurricane Packs As FEMA Urges Preparedness
10. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
11. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... FRANCISCO , May 23, 2016 ... to reach USD 5.0 billion by 2022, according to ... increasing generation of medical waste coupled with the lack ... industry is expected to drive the demand for reprocessed ... these devices as compared to that of the original ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The Society ... MSW, has decided to move on from that role. , “No one in Washington ... did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... to residents of Westchester County for over 24 years, recently hosted its sixth ... members joined HOW for two remembrance ceremonies, each concluding with the release of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... information management systems (LIMS), electronic laboratory notebook systems (ELNS) and related systems is ... manual data management consumes a significant amount of lab technician time and introduces ...
(Date:5/23/2016)... ... May 23, 2016 , ... SPH ... as Chief Medical Officer. Dr. O’Connor’s deep expertise in medicine and HIT will ... services teams who deliver best-in-class solutions and transformative technologies for provider, payer, and ...
Breaking Medicine News(10 mins):